» Articles » PMID: 30937199

A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia

Overview
Publisher Wiley
Specialty Hematology
Date 2019 Apr 3
PMID 30937199
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

A 67-year-old male, with a known diagnosis of myelodysplastic syndromes with multilineage dysplasia (MDS-MLD) was admitted to our hospital with a primary complaint of subcutaneous bleeding in his left thigh. Laboratory data showed anaemia and prolongation of activated partial thromboplastin time (85.8 s, normal range 24-39 s) without thrombocytopenia. Coagulation factor VIII (FVIII) activity was less than 1% (normal range 60-150%), and a FVIII inhibitor was identified and quantified at 166 BU/mL to indicate a diagnosis of acquired haemophilia A (AHA). A recent, but sustained circulating monocytosis (>1 × 10/L) was observed, which combined with elevated numbers of neutrophil and monocytic cells in the marrow, suggested evolution of MDS-MLD to chronic myelomonocytic leukaemia (CMML), coinciding with AHA. Further analysis revealed a karyotype of 46, XY, (14) (q10), which was the same abnormality previously identified in the patient. To treat bleeding caused by AHA, steroid and activated prothrombin complex concentrate were administered. Azacitidine (AZA) was used to treat CMML. During the clinical course, bleeding partially improved; however, subsequent acute myocardial infarction occurred on day 87. Worsening bone marrow failure was observed 4 months after the original admission, despite administration of AZA therapy, and the patient died due to bleeding from AHA. This case suggests that the evolution of MDS to CMML status can be associated with AHA conferring a bleeding tendency.

Citing Articles

Massive Right Atrial Thrombosis: Are You Brave Enough to Start Anticoagulation? A Case Report.

Bergonti M, Ascione C, Agostoni P, Castelli R, Vignati C Front Cardiovasc Med. 2021; 8:688351.

PMID: 34395558 PMC: 8362882. DOI: 10.3389/fcvm.2021.688351.


COVID-19 in a patient with chronic myelomonocytic leukemia: a twisting tale.

Jain A, Jain A, Prasad P, Chaudhry S, Sharma M, Khunger J Blood Res. 2020; 55(4):278-281.

PMID: 33380560 PMC: 7784132. DOI: 10.5045/br.2020.2020230.

References
1.
Ehrlich H, Henzl M, Gomperts E . Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002; 8(2):83-90. DOI: 10.1046/j.1365-2516.2002.00532.x. View

2.
Biss T, Crossman L, Neilly I, Hanley J . An acquired factor VIII inhibitor in association with a myeloproliferative/myelodysplastic disorder presenting with severe subcutaneous haemorrhage. Haemophilia. 2003; 9(5):638-41. DOI: 10.1046/j.1365-2516.2003.00806.x. View

3.
Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R . A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol. 2003; 124(1):86-90. DOI: 10.1046/j.1365-2141.2003.04731.x. View

4.
Welborn J . Acquired Robertsonian translocations are not rare events in acute leukemia and lymphoma. Cancer Genet Cytogenet. 2004; 151(1):14-35. DOI: 10.1016/j.cancergencyto.2003.09.019. View

5.
Collins P, Hirsch S, Baglin T, Dolan G, Hanley J, Makris M . Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2006; 109(5):1870-7. DOI: 10.1182/blood-2006-06-029850. View